Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Department of Justice
Farmers Insurance
Medtronic
Dow
Merck
Argus Health
Citi
AstraZeneca

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,501,164

« Back to Dashboard

Which drugs does patent 8,501,164 protect, and when does it expire?

Patent 8,501,164 protects NICORETTE and is included in one NDA.

This patent has seventeen patent family members in sixteen countries.
Summary for Patent: 8,501,164
Title:Nicotine lozenge compositions
Abstract: The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.
Inventor(s): Chen; Li-Lan (Parsippany, NJ)
Assignee: GlaxoSmithKline, LLC (Philadelphia, PA)
Application Number:12/990,049
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 8,501,164

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-001 May 18, 2009 OTC Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,501,164

PCT Information
PCT FiledApril 30, 2009PCT Application Number:PCT/US2009/042190
PCT Publication Date:November 05, 2009PCT Publication Number: WO2009/134947

Non-Orange Book US Patents Family Members for Patent 8,501,164

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,940,772 Nicotine lozenge composition ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,501,164

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2011519862 ➤ Try a Free Trial
Hungary E031175 ➤ Try a Free Trial
Hong Kong 1153146 ➤ Try a Free Trial
Spain 2605244 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cerilliant
Federal Trade Commission
Harvard Business School
US Army
Queensland Health
AstraZeneca
Chinese Patent Office
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.